Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 5
2017 2
2018 1
2019 5
2020 3
2021 8
2022 2
2023 4
2024 6
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S. Fishbane S, et al. J Am Soc Nephrol. 2019 Sep;30(9):1723-1733. doi: 10.1681/ASN.2019050450. Epub 2019 Jun 14. J Am Soc Nephrol. 2019. PMID: 31201218 Free PMC article. Clinical Trial.
The DIALIZE study (NCT03303521) evaluated sodium zirconium cyclosilicate (SZC) in the management of hyperkalemia in hemodialysis patients. ...Rescue therapy to reduce serum potassium during the treatment period was required by 2.1% of patients taking sodium zirco …
The DIALIZE study (NCT03303521) evaluated sodium zirconium cyclosilicate (SZC) in the management of hyperkalemia in hemodialys …
Hyperkalemia in chronic kidney disease.
Watanabe R. Watanabe R. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s31-s36. doi: 10.1590/1806-9282.66.S1.31. Rev Assoc Med Bras (1992). 2020. PMID: 31939533 Free article. Review.
This increase in serum potassium levels is associated with decreased renal ion excretion, as well as the use of medications to reduce the progression of CKD or to control associated diseases such as diabetes mellitus and heart failure. ...
This increase in serum potassium levels is associated with decreased renal ion excretion, as well as the use of medications to reduce …
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
Roger SD, Spinowitz BS, Lerma EV, Singh B, Packham DK, Al-Shurbaji A, Kosiborod M. Roger SD, et al. Am J Nephrol. 2019;50(6):473-480. doi: 10.1159/000504078. Epub 2019 Oct 28. Am J Nephrol. 2019. PMID: 31658466 Free PMC article. Clinical Trial.
BACKGROUND: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for treatment of hyperkalemia. ...
BACKGROUND: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for treatment of hyperkal …
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2020 Jun 26;6(6):CD013165. doi: 10.1002/14651858.CD013165.pub2. Cochrane Database Syst Rev. 2020. PMID: 32588430 Free PMC article.
Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and other adverse gastrointestinal (GI) symptoms, reducing their tolerability. Patiromer and sodium zirconium cyclosilicate are ne …
Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and …
Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders.
Fonseca C, Garagarza C, Silva G, Caires G, Marques I, Lopes JA, Branco P, Alves R, Ferreira A. Fonseca C, et al. Heart Fail Rev. 2025 Mar;30(2):271-286. doi: 10.1007/s10741-024-10461-3. Epub 2024 Nov 27. Heart Fail Rev. 2025. PMID: 39604607 Free PMC article. Review.
In recent years, the development of new potassium binders, specifically patiromer and sodium zirconium cyclosilicate (SZC), has revolutionized the management of hyperkalemia. Patiromer, a non-absorbed polymer, binds potassium in the gastrointestinal tract in exchang …
In recent years, the development of new potassium binders, specifically patiromer and sodium zirconium cyclosilicate (SZC), ha …
The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer.
Desai NR, Kammerer J, Budden J, Olopoenia A, Tysseling A, Gordon A. Desai NR, et al. Kidney360. 2024 Dec 1;5(12):1835-1843. doi: 10.34067/KID.0000000586. Epub 2024 Sep 20. Kidney360. 2024. PMID: 39303023 Free PMC article.
KEY POINTS: One previous study using claims data reported signals for higher hospitalizations for heart failures and severe edema in patients prescribed a potassium binder using sodium exchange. In this study, sodium zirconium cyclosilicate use was associated with i …
KEY POINTS: One previous study using claims data reported signals for higher hospitalizations for heart failures and severe edema in patient …
Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K, Dhawan P, Nobakht N, Kamgar M, Goshtaseb R, Sarmosyan K, Gnarini M, Wassef O, Lerma E. Rastogi A, et al. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1055-1064. doi: 10.1080/17512433.2021.1932460. Epub 2021 Jul 6. Expert Rev Clin Pharmacol. 2021. PMID: 34227913 Review.
The concern of gastrointestinal (GI) adverse effects with sodium polystyrene sulfonate has spurred the development of alternatives. Sodium zirconium cyclosilicate (SZC) is a promising agent that selectively binds potassium in the gut and eliminates it, while being s …
The concern of gastrointestinal (GI) adverse effects with sodium polystyrene sulfonate has spurred the development of alternatives. Sodium …
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S. Fishbane S, et al. BMC Nephrol. 2022 Feb 8;23(1):59. doi: 10.1186/s12882-021-02569-7. BMC Nephrol. 2022. PMID: 35135481 Free PMC article. Clinical Trial.
BACKGROUND: Sodium zirconium cyclosilicate (SZC) is an effective and well-tolerated treatment for hyperkalemia in maintenance hemodialysis patients. ...
BACKGROUND: Sodium zirconium cyclosilicate (SZC) is an effective and well-tolerated treatment for hyperkalemia in maintenance …
Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.
Packham DK, Kosiborod M. Packham DK, et al. Expert Opin Drug Metab Toxicol. 2016 May;12(5):567-73. doi: 10.1517/17425255.2016.1164691. Epub 2016 Apr 5. Expert Opin Drug Metab Toxicol. 2016. PMID: 26998854 Review.
INTRODUCTION: Hyperkalemia is a common electrolyte disorder that arises from dysfunctional homeostatic mechanisms or as a consequence of decreased renal function. Sodium zirconium cyclosilicate (ZS-9) is a potential new therapy for hyperkalemia in both acute and chr …
INTRODUCTION: Hyperkalemia is a common electrolyte disorder that arises from dysfunctional homeostatic mechanisms or as a consequence of dec …
Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences.
Fernandez-Prado R, Villalvazo P, Avello A, Gonzalez-de-Rivera M, Aguirre M, Carrasco-Muñoz CG, Fernandez-Fernandez B, Martin-Cleary C, Carriazo S, Sanchez-Niño MD, Perez-Gomez MV, Ortiz A. Fernandez-Prado R, et al. Biomed Pharmacother. 2023 Feb;158:114197. doi: 10.1016/j.biopha.2022.114197. Epub 2023 Jan 4. Biomed Pharmacother. 2023. PMID: 36916426 Free article. Review.
Clinical guidelines recommend a target serum bicarbonate 22 mmol/L, but metabolic acidosis frequently remains undiagnosed and untreated. Sodium zirconium cyclosilicate (SZC) binds potassium in the gut and is approved to treat hyperkalemia. ...Mechanistically, thes …
Clinical guidelines recommend a target serum bicarbonate 22 mmol/L, but metabolic acidosis frequently remains undiagnosed and untreated. S …
39 results